228MO PALOMA-4: Primary results from a phase III trial of palbociclib (PAL) + letrozole (LET) vs placebo (PBO) + LET in Asian postmenopausal women with estrogen receptor–positive/human epidermal growth factor receptor 2–negative (ER+/HER2–) advanced breast cancer (ABC)

B Xu,X Hu,W Li,T Sun,K Shen,S Wang,Y Cheng,Q Zhang,S Cui,Z Tong,C Geng,C-S Huang,V Sriuranpong,K.C.R Ngan,Y.H Chia,X Wang,H Zhao

doi:10.1016/j.annonc.2021.08.511

228MO PALOMA-4: Primary results from a phase III trial of palbociclib (PAL) + letrozole (LET) vs placebo (PBO) + LET in Asian postmenopausal women with estrogen receptor–positive/human epidermal growth factor receptor 2–negative (ER+/HER2–) advanced breast cancer (ABC)

B Xu, X Hu + Show 15 more

Open Access

https://doi.org/10.1016/j.annonc.2021.08.511

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology	Publication Date: Sep 1, 2021
Citations: 9	License type: publisher-specific-oa

Affiliation: Cancer Hospital of Chinese Academy of Medical Sciences, Fudan University Shanghai Cancer Center, First Hospital of Jilin University, Shanghai Jiao Tong University, Sun Yat-sen University Cancer Center, Third Affiliated Hospital of Harbin Medical University, Fourth Hospital of Hebei Medical University, National Taiwan University Hospital, King Chulalongkorn Memorial Hospital, University of Hong Kong

#Asian Women #Breast Cancer In Asian Women + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

The incidence of breast cancer in Asian women has increased rapidly over the past 40 years. A previous subgroup analysis from PALOMA-2 indicated that PAL + LET may be effective as first-line therapy in postmenopausal Asian women with ER+/HER2– ABC. The PALOMA-4 study assessed the efficacy and safety of PAL + LET in Asian patients (pts).

Full Text